[HTML][HTML] Effect of oral nirmatrelvir on long COVID symptoms: 4 cases and rationale for systematic studies
MJ Peluso, K Anglin, MS Durstenfeld… - Pathogens and …, 2022 - ncbi.nlm.nih.gov
Pathogens and Immunity, 2022•ncbi.nlm.nih.gov
Background: Efforts to understand the impact of SARS-CoV-2 variants, vaccine status, and
treatment on the development and persistence of Long COVID have intensified. Methods:
We report 4 sequential cases from a post-COVID cohort study demonstrating variability in
outcomes following differentially timed nirmatrelvir therapy, received as part of clinical care.
Results: In the first case, the participant experienced symptomatic rebound and developed
Long COVID despite early initiation of antiviral therapy. In the next 2 cases, participants …
treatment on the development and persistence of Long COVID have intensified. Methods:
We report 4 sequential cases from a post-COVID cohort study demonstrating variability in
outcomes following differentially timed nirmatrelvir therapy, received as part of clinical care.
Results: In the first case, the participant experienced symptomatic rebound and developed
Long COVID despite early initiation of antiviral therapy. In the next 2 cases, participants …
Abstract
Background:
Efforts to understand the impact of SARS-CoV-2 variants, vaccine status, and treatment on the development and persistence of Long COVID have intensified.
Methods:
We report 4 sequential cases from a post-COVID cohort study demonstrating variability in outcomes following differentially timed nirmatrelvir therapy, received as part of clinical care.
Results:
In the first case, the participant experienced symptomatic rebound and developed Long COVID despite early initiation of antiviral therapy. In the next 2 cases, participants reported improvement in persistent COVID symptoms when nirmatrelvir was taken 25 and 60 days following initial symptom onset. In the final case, an individual with presumed Long COVID for 2 years reported substantial improvement in chronic symptoms when taking nirmatrelvir following SARS-CoV-2 re-infection.
Conclusions:
These anecdotes suggest that systematic study of antiviral therapy for Long COVID is warranted.
ncbi.nlm.nih.gov
